What are Adenosine A2A receptor antagonist drugs?

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Adenosine A2A receptor antagonist drugs are pharmacologic agents that share a common mechanism (typically targeting Adenosine A2A receptor). 0 are currently marketed, with 6 more in clinical development.

Adenosine A2A receptor antagonist

0 marketed 2 in Phase 3 4 in Phase 2

This page covers all Adenosine A2A receptor antagonist drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Adenosine A2A receptor, adenosine A2A receptor, Adenosine A2A receptor (A2AR).

Targets

Adenosine A2A receptor · adenosine A2A receptor · Adenosine A2A receptor (A2AR) · A2A receptor

Phase 3 pipeline (2)

AD109 · Apnimed · Oncology
AD109 is an adenosine A2A receptor antagonist that blocks inhibitory signaling in the tumor microenvironment to enhance immune cell activation.
Istradefylline (KW-6002) · Kyowa Kirin, Inc. · Neurology
Istradefylline is an adenosine A2A receptor antagonist that blocks inhibitory signaling in the basal ganglia, thereby enhancing dopaminergic motor control.

Phase 2 pipeline (4)

AZD4635 · AstraZeneca · Oncology
AZD4635 is a small molecule inhibitor of the adenosine A2A receptor.
AD 237 · Sosei · Oncology
AD 237 is a selective antagonist of the adenosine A2A receptor that blocks immunosuppressive signaling in the tumor microenvironment.
AZD5148 · AstraZeneca · Oncology
AZD5148 is a selective, potent and orally bioavailable adenosine A2A receptor antagonist.
AZD8529 · AstraZeneca · Oncology
AZD8529 is a selective adenosine A2A receptor antagonist.

Patent intelligence

adenosine a2a receptor antagonist patent landscape — aggregated cliff calendar, attackable patents, originator estates